Loading...
SITCSection 5
U.S. imports of other hormone medicaments (non-insulin, non-adrenal cortical), dosage form or retail packings (SITC 54229) totaled $1.0B in July 2026, traded with 33 countries.
Importers of Other Hormone Medicaments (Non-Insulin, Non-Adrenal Cortical), Dosage Form or Retail Packings paid $536K in duties in July 2026 — an effective duty rate of 10% on $5.4M in dutiable value, based on actual customs collections rather than the published tariff schedule. Other Hormone Medicaments (Non-Insulin, Non-Adrenal Cortical), Dosage Form or Retail Packings imports of $1.0B in July 2026 ran 46% above the year-to-date monthly average of $690.0M.
Last updated: July 2026 dataFinished medicaments containing hormones, hormone derivatives, and steroids used as hormones — excluding insulin and adrenal cortical hormones — in dosage or retail form cover a commercially diverse range of products including sex hormones, thyroid hormones, growth hormones, and synthetic analogs used in endocrinology, oncology, and reproductive medicine. FDA admissibility review applies, and certain anabolic steroid products in this category also require DEA import authorization as Schedule III controlled substances. The NES designation makes this a residual heading, so classification accuracy depends on ruling out insulin and adrenal cortical hormone content first. Importers of biosimilar growth hormones should confirm FDA licensure status before shipment.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
882 shipments/mo
Combination hormone products present a genuine classification challenge. The applicable heading depends on which active ingredient is considered primary under the relevant classification rules, and the adrenal cortical hormone heading may take precedence if that component drives the product's therapeutic use. This is an edge case where a licensed customs broker or trade attorney with pharmaceutical classification experience should be consulted before entry.
Recombinant human growth hormone (somatropin) is regulated as a biologic under the Public Health Service Act, so the foreign manufacturer must hold an FDA biologics license or have an approved biosimilar application. Additionally, growth hormone is a controlled substance under the Anabolic Steroid Control Act in certain contexts, and its importation for non-approved uses is restricted. Importers should confirm both FDA licensure and any applicable DEA requirements before shipment.
ImportsExports
Imports
$1.0BYoY · Pro
Exports
$602.4MYoY · Pro
12-mo low · imports
YoY · ProThrough July 2026. Source: U.S. Census Bureau.
Imports · July 2026
origin
China and Ireland together supply 67% of it.
customs district
Census does not publish district detail for this classification system.
destination
Census does not publish state detail for this classification system.
entry
Census does not publish port detail for this classification system.
Supplier Network
Get discovered by U.S. importers searching for HS 54229 — Other Hormone Medicaments (Non-Insulin, Non-Adrenal Cortical), Dosage Form or Retail Packings. Be the first supplier listed.